drugset / Trial / NCT00918281
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Phase 2
Completed
70 enrolled
GE Healthcare
BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses) · collabQuintiles, Inc. · collabi3 Statprobe · collab
NaSingle-groupOpen-labelDiagnostic
Summary
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET acquisitions, and tumors demonstrate detectable levels of 18F uptake on PET.
Timeline
- Start
- 2009-06
- Primary completion
- 2011-09
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluciclatide | Peptide | — | Intravenous |